XOMA to Host XOMA 358 Clinical Update Webcast and Conference Call on September 15, 2016
September 06 2016 - 9:00AM
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and
development of therapeutic antibodies, announced today it will host
a webcast and conference call on September 15, 2016, at 1:30 p.m.
PDT (4:30 p.m. EDT), to provide an update on the ongoing XOMA 358
Phase 2 proof-of-concept clinical program in congenital
hyperinsulinism (CHI) and hypoglycemia post-bariatric surgery
(PBS), two rare medical conditions resulting from abnormal insulin
secretion.
The presentation slides and webcast can be accessed via the
Investors and Media section of XOMA’s website at
http://investors.xoma.com/events.cfm and will be available for
replay until close of business on December 15, 2016. Telephone
numbers for the live audiocast are 877-369-6589 (U.S./Canada) and
408-337-0122 (international) with the passcode 75822110.
About XOMA 358Insulin is the major physiologic
hormone for controlling blood glucose levels. Abnormal increases in
insulin secretion can lead to profound hypoglycemia (low blood
sugar), a state that can result in significant morbidities,
including brain damage, seizures and epilepsy. XOMA, leveraging its
scientific expertise in allosteric monoclonal antibodies, developed
the XMet platform, consisting of separate classes of selective
insulin receptor modulators (SIRMs) that could have a major effect
on treating patients with abnormal metabolic states.
XOMA 358 is a fully human negative allosteric modulating insulin
receptor antibody derived from the XMet platform. It is being
investigated as a novel treatment for non-drug-induced, endogenous
hyperinsulinemic hypoglycemia (low blood glucose caused by
excessive insulin production), as well as hypoglycemia after
bariatric surgery and other related disorders. XOMA is conducting
Phase 2 development activities for XOMA 358 in patients with
congenital hyperinsulinism (CHI) and in patients with hypoglycemia
post-bariatric surgery (PBS). A therapy that safely and effectively
mitigates insulin-induced hypoglycemia has the potential to address
a significant unmet therapeutic need for certain rare medical
conditions associated with hyperinsulinism. More information on the
XOMA 358 clinical trial can be found at www.clinicaltrials.gov and
www.clinicaltrialsregister.eu.
About Congenital Hyperinsulinismi, ii, iii,
ivCongenital hyperinsulinism (CHI) is a genetic disorder
in which the insulin cells of the pancreas (beta cells) secrete
inappropriate and excessive insulin. Ordinarily, beta cells secrete
just enough insulin to keep blood sugar in the normal range. In
people with CHI, the secretion of insulin is not properly
regulated, causing excess insulin secretion and frequent episodes
of low blood sugar (hypoglycemia). In infants and young children,
these episodes are characterized by a lack of energy (lethargy),
irritability or difficulty feeding. Repeated episodes of low blood
sugar increase the risk for serious complications, such as
breathing difficulties, seizures, intellectual disability, vision
loss, brain damage, coma and possibly death. About 60 percent of
infants with CHI experience a hypoglycemic episode within the first
month of life. Other affected children develop hypoglycemia by
early childhood. Current treatments for CHI are limited to medical
therapy and surgical removal of part or all of the pancreas
(pancreatectomy).
About Hypoglycemia Post-Bariatric SurgeryAs the
number of gastric bypass surgeries to treat severe obesity has
increased, so too has the awareness that this population may
experience postprandial hypoglycemia (low blood glucose following a
meal) with symptoms developing months or years following the
gastric bypass surgery. Postprandial hypoglycemia occurs with a
range of severity in post-bariatric surgery patients. The mild
end of the spectrum may be managed largely through diet
modification. The most severe forms are more prevalent in
patients who underwent a Roux-en-Y procedure, and result in severe
refractory postprandial hyperinsulinemic hypoglycemia with
neuroglycopenic symptoms (altered mental status, loss of
consciousness, seizures) that cannot be managed through diet
modification. If currently available pharmacologic agents do
not resolve the condition, these patients are treated with either a
partial pancreatectomy or reversal of the gastric bypass.
About XOMA CorporationXOMA Corporation is a
leader in the discovery and development of therapeutic antibodies.
The Company's innovative product candidates result from its
expertise in developing ground-breaking monoclonal antibodies,
including allosteric antibodies, which have created new
opportunities to potentially treat a wide range of human diseases.
XOMA's scientific research has produced a portfolio of five
endocrine assets, each of which has the opportunity to address
multiple indications. The Company's lead product candidate, XOMA
358, is a negative allosteric monoclonal antibody that reduces
insulin receptor activity, which could have a major impact on the
treatment of hyperinsulinism. The Company is conducting Phase 2
development activities for XOMA 358 in patients with congenital
hyperinsulinism and in patients with hypoglycemia after bariatric
surgery. For more information, visit www.xoma.com.
Forward-Looking StatementsCertain statements
contained in this press release including, statements related to
anticipated timing of clinical trials, anticipated timing of the
release of clinical data, regulatory approval of unapproved product
candidates, the anticipated process of clinical data analysis, the
anticipated success of any clinical trial, cash usage, or
statements that otherwise relate to future periods are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These statements are based on assumptions that may not
prove accurate, and actual results could differ materially from
those anticipated due to certain risks inherent in the
biotechnology industry and for companies engaged in the development
of new products in a regulated market. Potential risks to XOMA
meeting these expectations are described in more detail in XOMA's
most recent filing on Form 10-K and in other SEC filings. Consider
such risks carefully when considering XOMA's prospects. Any
forward-looking statement in this press release represents XOMA's
views only as of the date of this press release and should not be
relied upon as representing its views as of any subsequent date.
XOMA disclaims any obligation to update any forward-looking
statement, except as required by applicable law.
i ghr.nlm.nih.gov/condition/congenital-hyperinsulinism.
Accessed June 11, 2015.
ii
www.chop.edu/conditions-diseases/congenital-hyperinsulinism/about#.VXncFU3bKHt.
Accessed June 11, 2015.
iii
www.chop.edu/conditions-diseases/congenital-hyperinsulinism/about#.VXneYE3bKHu.
Accessed June 11, 2015.
iv www.ojrd.com/content/pdf/1750-1172-6-63.pdf. Accessed June
11, 2015.
CONTACT: XOMA Corporation
Company and investor contact:
Ashleigh Barreto
510-204-7482
barreto@xoma.com
Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com
Media contact:
Taryn Ibach
W2O Group
415-658-9748
tibach@w2ogroup.com
XOMA Royalty (NASDAQ:XOMA)
Historical Stock Chart
From Aug 2024 to Sep 2024
XOMA Royalty (NASDAQ:XOMA)
Historical Stock Chart
From Sep 2023 to Sep 2024